Advertisement
UK markets closed
  • FTSE 100

    8,315.86
    +102.37 (+1.25%)
     
  • FTSE 250

    20,393.09
    +228.55 (+1.13%)
     
  • AIM

    776.06
    +4.53 (+0.59%)
     
  • GBP/EUR

    1.1637
    -0.0022 (-0.19%)
     
  • GBP/USD

    1.2542
    -0.0021 (-0.17%)
     
  • Bitcoin GBP

    50,930.67
    +415.27 (+0.82%)
     
  • CMC Crypto 200

    1,323.88
    -41.25 (-3.02%)
     
  • S&P 500

    5,194.11
    +13.37 (+0.26%)
     
  • DOW

    38,930.03
    +77.76 (+0.20%)
     
  • CRUDE OIL

    78.20
    -0.28 (-0.36%)
     
  • GOLD FUTURES

    2,324.00
    -7.20 (-0.31%)
     
  • NIKKEI 225

    38,835.10
    +599.03 (+1.57%)
     
  • HANG SENG

    18,479.37
    -98.93 (-0.53%)
     
  • DAX

    18,438.17
    +262.96 (+1.45%)
     
  • CAC 40

    8,076.61
    +79.97 (+1.00%)
     

JNJ or PFE: Comparing Legacy and Newly Launched Immunology Drugs

JNJ or PFE: Comparing Legacy and Newly Launched Immunology Drugs

Johnson & Johnson or Pfizer: Which Is the Best Pick in April?(Continued from Prior Part)Legacy immunology drugs In the first quarter, Johnson & Johnson (JNJ) reported Remicade sales worth $1.10 billion, a YoY (year-over-year) fall of 20.6% on